CD36 is a cell-surface protein comprising 472 aminoacid residues that is predicted to be anchored to the plasma membrane by two transmembrane domains. 1, 2) It is expressed in a variety of cells, including monocytes/ macrophages, platelets, and vascular endothelial cells, and is known to mediate the cellular uptake of structurally unrelated substances, such as oxidized low-density lipoprotein (oxLDL) and the advanced glycation end products on proteins. [1] [2] [3] [4] [5] These characteristics suggest that CD36 functions as a molecular mediator in cellular clearance of the substances intimately involved in aging processes, diabetic complications, and atherosclerosis. [6] [7] [8] CD36 is also believed to be involved in the cellular uptake, trafficking, and metabolism of long-chain fatty acids. 9, 10) The expression of CD36 in cells, including adipocytes, enterocytes, skeletal myocytes, and taste bud cells, confirms this. 1, 2, 9, 11) However, it remains to be seen how the protein recognizes long-chain fatty acids, particularly in the cell-surface microenvironment. 12) oxLDL is known to serve as a high-affinity ligand of CD36, and hence its binding characteristics have been extensively studied. 1, 3, 13) An important finding is that CD36-dependent recognition of oxLDL is mediated principally by oxidized glycerophospholipids (oxPLs), which are formed during the oxidation of LDL. 13, 14) This was determined by the ability of small unilamellar vesicles containing oxPLs to inhibit the binding of oxLDL to human embryonic kidney HEK293 cells stably transfected with human CD36 cDNA. Direct binding of oxPLs-containing vesicles to the CD36 cDNA-transfected cells was also shown. As a consequence of oxidation, an sn-2 acyl group of phospholipids on the surfaces of the LDL particles incorporates a terminal -hydroxyl(or oxo)-,-unsaturated carbonyl, and thereby is partitioned into the aqueous phase. The oxidized sn-2 acyl chain probably serves as an essential structural context for high-affinity binding of oxLDL to CD36 in an aqueous milieu. 13, 14) A site on CD36 critical for oxLDL/oxPL binding has also been investigated. Using glutathione S-transferase (GST)-CD36 fusion proteins produced in E. coli, Podrez and co-workers found that the region spanning CD36 amino acids 118 to 182 contains a binding site for oxLDL/oxPL and that lysine residues 164/166 are indispensable for binding. 15) They also found that a synthetic peptide corresponding to amino acids 154 to 168 of human CD36 (Fig. 1A) effectively inhibits the binding of oxLDL to CD36-expressing HEK293 cells and to a GST-CD36 fusion protein (designated as GST-CD36 118{182 ) immobilized onto glutathione-coated beads, indicating that this region (154-168) largely accounts for high-affinity binding to oxLDL/oxPL.
To date, cultured mammalian cells transfected with CD36 cDNA have been used mostly in experiments to assess the binding of oxLDL/oxPL, [13] [14] [15] but such an experimental system has a number of shortcomings, y To whom correspondence should be addressed. Fax: +81-75-753-6264; E-mail: tkmone@kais.kyoto-u.ac.jp Abbreviations: DiI, 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate; DMEM, Dulbecco's Modified Eagle's Medium; AFL, Alexa Fluor Ò 488-labeled; GST, glutathione S-transferase; KDdiA-PC, 1-palmitoyl-2-(4-ketododec-3-enedioyl)phosphatidylcholine; KOdiA-PC, 1-(palmitoyl)-2-(5-keto-6-octenedioyl)phosphatidylcholine; oxLDL, oxidized low-density lipoprotein; oxPLs, oxidized glycerophospholipids; PAPC, 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphocholine; PC, phosphatidylcholine including high cost, time-consuming protocols, and experiment-to-experiment variability. In addition, the endogenous expression of protein of interest and related molecules in the cell line used as host can occasionally lead to incorrect interpretations. As described above, GST-CD36 fusion proteins expressed in and purified from E. coli have been applied successfully for this purpose, 15) but it is generally difficult to ensure batch-tobatch consistency in bacterially expressed recombinant proteins. In the present study, we aimed to devise a fast, reliable, and easily reproducible assay to detect binding between CD36 and oxLDL/oxPL. For this purpose, we prepared N-terminally-biotinylated CD36 peptides harboring the putative site on mouse CD36 for oxLDL/ oxPL binding, and investigated the ability of the peptides immobilized onto streptavidin-coated plates to interact with oxLDL/oxPL. Here we report that a peptide corresponding to amino acids 149 to 168 of CD36 can be used for this purpose.
Materials and Methods

Materials. Alexa Fluor
Ò 488 reactive dye, Alexa Fluor Ò 488 carboxylicacid, trifluorophenyl ester, bis(triethylammoniumsalt), and cell culture reagents were purchased from Invitrogen (Carlsbad, CA). A fatty acid-free bovine serum albumin (BSA) and a phosphatidylcholine (PC) species, 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (hereinafter PAPC), were from Sigma (St. Louis, MO). Human oxLDL, 2 mg/mL in phosphate buffered saline (PBS, 8 mM Na 2 HPO 4 , 1.5 mM KH 2 PO 4 , 136 mM NaCl, and 2.7 mM KCl, pH 7.4) containing 0.1 mM EDTA, with a thiobarbituric acid-reactive substance value of about 30 moles of malondialdehyde/mg protein and human oxLDL labeled with 1,1 0 -dioctadecyl-3,3,3 0 ,3 0 -tetramethylindocarbocyanine perchlorate (DiI) were from Biomedical Technologies (Stoughton, MA). KDdiA-PC, or 1-palmitoyl-2-(4-ketododec-3-enedioyl)-PC and KOdiA-PC, or 1-(palmitoyl)-2-(5-keto-6-octenedioyl)-PC, were from Cayman Chemical (Ann Arbor, MI). Peptides conjugated with biotin at the N-termini, biotin-CD36 154{168 , biotin-CD36 149{168 , biotin-CD36 149{168 (scramble), and biotin-CD36 149{168 (K164E/K166E) (Fig. 1A) , were synthesized by and purchased from Bonac (Fukuoka, Japan). The other chemicals used were of the best grade available from commercial sources.
Labeling of oxLDL with a fluorescence dye. oxLDL was fluorescence labeled using an Alexa Fluor Ò 488. 16 ) First, 0.5 mL of oxLDL solution was dialyzed 4 times against 0.25 L of ice-cold 50 mM sodium bicarbonate solution for 30 min. Then the dialyzed solution was added to a vial containing the reactive dye in powdered form, and this was incubated with stirring in the dark for 1 h at ambient temperature (20 to 25 C). After incubation, the reaction mixture was dialyzed 4 times in the dark against 0.25 L of ice-cold PBS containing 0.001% w/v sodium azide for 1 h to terminate the cross-coupling reaction and to remove unreacted dyes. A solution containing oxLDL labeled with Alexa Fluor Ò 488 (hereinafter AFL-oxLDL) solution was aliquoted into amber glass vials and stored at 4 C until use.
Pretreatment of avidin-coated plates with synthetic peptides and evaluation of the interaction of the peptides with AFL-oxLDL. Each of the CD36 peptides was dissolved in dimethylsulfoxide at a concentration of 10 mM, and stored at À20 C until use. The wells of a 96-well plate precoated with streptavidin (Thermo Fisher Scientific Japan, Tokyo) were prewashed 3 times with PBS containing 0.4% w/v BSA (hereinafter PBS-BSA). A 0.1-mL aliquot of PBS-BSA alone or of PBS-BSA containing the biotinylated peptides at a certain concentration (e.g., 50 mM) was added to each of the individual wells of the plate. Then the plate was incubated for 1 h at ambient temperature with gentle shaking. After washing 3 times with PBS-BSA, each well received 0.1 mL of PBS-BSA containing AFL-oxLDL at a certain concentration (e.g., 8mg/mL) in the presence and the absence of nonlabeled oxLDL (e.g., 0.64 mg/mL) that had been dialyzed extensively against ice-cold PBS. Then the plate was incubated in the dark for 1 h at ambient temperature with gentle shaking. After incubation, the wells were washed 3 times with 0.3 mL of PBS and then exposed to 0.1 mL of PBS. The fluorescence in each well was measured using a plate reader (PowerScan, Dainippon Sumitomo Pharma, Osaka, Japan) at an excitation wavelength of 485 nm and an emission wavelength of 528 nm.
Determination of the dissociation constant (K d ) and the binding maximum (B max ) of AFL-oxLDL binding to biotin-CD36 149{168 . Wells pretreated with 50 mM biotin-CD36 149{168 were exposed to 0.1 mL of PBS-BSA containing various concentrations of AFL-oxLDL in the absence and the presence of 0.64 mg/mL of nonlabeled oxLDL, and the assay plate was incubated as described above. After incubation, the assay solutions were harvested and diluted 100-fold with PBS, and the fluorescence values (representing the concentrations of free ligand) were determined as described above. After harvesting of the assay solutions, the fluorescence of each well was measured as described above. The fluorescence value in each well was obtained by subtracting the mean background value of the wells that had been incubated with PBS-BSA alone (PBS-BSA containing no AFL-oxLDL). At each concentration of AFL-oxLDL, the value for specific binding (the amount of AFL-oxLDL bound to immobilized biotin-CD36 149{168 in a Wells of streptavidin-coated plates were pretreated with PBS-BSA alone (None), PBS-BSA containing 50 mM biotin-CD36 154{168 (154-168), PBS-BSA containing 50 mM biotin-CD36 149{168 (149-168), PBS-BSA containing 50 mM biotin-CD36 154{168 (scramble) (Scramble), or PBS-BSA containing 50 mM biotin-CD36 149{168 (K164E/K166E) (K164E/K166E). The wells were then incubated with PBS-BSA containing 8 mg/mL of AFL-oxLDL in the absence (Ànonlabeled oxLDL) and the presence (þnonlabeled oxLDL) of 0.64 mg/mL nonlabeled oxLDL. The mean fluorescence value for the wells pretreated with PBS-BSA alone and then incubated with AFL-oxLDL alone was taken to be 1.0. Data are expressed as the mean AE SD for three independent wells. well) was obtained by subtracting the mean fluorescence value in the presence of nonlabeled oxLDL (nonspecific binding) from the fluorescence value in the absence of nonlabeled oxLDL (total binding). The values of K d and B max were determined by fitting the progress curve to the theoretical curve by equation (1) with the aid of commercially available software (Prism, GraphPad, San Diego, CA):
where B is the amount of AFL-oxLDL bound to immobilized biotin-CD36 149{168 in a well, and [L] is the concentration of free AFLoxLDL. 17) The amounts of AFL-oxLDL bound to the peptide and the concentrations of free AFL-oxLDL were assessed by comparing them with the fluorescence values of the wells that received 0.1 mL of PBS containing AFL-oxLDL particles of known concentrations.
Assays in the presence of PL species. KDdiA-PC and KOdiA-PC were supplied at a concentration of 1% w/v (14 and 15 mM respectively) in ethanol. Thus, PAPC was dissolved in ethanol at a concentration of 1% w/v (13 mM). The dilution series of the PC species were prepared as follows: A 10-mL aliquot of each PC-containing solution was placed in a 1.5-mL microcentrifuge tube, and the tube received 90 mL of a concentrated solution of PBS (1:1 Â concentrate) containing 0.44% w/v BSA. The mixtures were subjected to brief sonication and diluted with PBS-BSA containing 10% v/v ethanol to make a dilution series. Each of the dilution series was then diluted 2-fold with PBS-BSA containing 16 mg/mL of AFL-oxLDL and used in experiments.
Wells pretreated with 50 mM biotin-CD36 149{168 were exposed to 0.1 mL of PBS-BSA containing 8 mg/mL of AFL-oxLDL in the absence and the presence of various concentrations of PL species, and the assay plate was incubated as described above. The fluorescence value for each well was measured as described above.
The inhibition pattern of KDdiA-PC toward AFL-oxLDL-biotin-CD36 149{168 binding was determined as follows: Wells pretreated with 50 mM biotin-CD36 149{168 were exposed to 0.1 mL of PBS-BSA containing various concentrations of AFL-oxLDL in the presence of 0.25 mM KDdiA-PC or 0.64 mg/mL nonlabeled oxLDL, and the assay plate was incubated as described above. The K d and B max values in the presence of KDdiA-PC were determined as described above. Equation (2) was used to calculate the inhibitor constant (K i ) of KDdiA-PC for AFL-oxLDL-biotin-CD36 149{168 binding:
where K 0 d is the K d value in the presence of KDdiA-PC, and [I] is the concentration of KDdiA-PC. 17) Procedures for transient transfection of cDNA for full-length CD36 into COS-1 cells and determination of K d and B max values for the binding of AFL-oxLDL to transfected cells. The procedure for the construction of a plasmid for the expression of full-length mouse CD36 using pcDNA3.1(þ) vector (Invitrogen) was described previously. 16) This expression plasmid has been designated pcDNA-mCD36. 16) COS-1 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum, 100 IU/mL of penicillin, and 100 IU/mL of streptomycin at 37 C in 5% CO 2 . The trypsinized cells were plated on a 6-well culture plate (Asahi Techno Glass, Tokyo) at a density of 2:0 Â 10 5 cells per well for transient expression. Twenty-four h after plating, transfection of pcDNA-mCD36 or parental pcDNA3.1(þ) vector into the cells was effected using Lipofectamine Ò 2000 (Invitrogen). Transfection was performed as follows: A 0.3-mL aliquot of serum-free DMEM received 4.8 mL of plasmid DNA solutions (1 mg/mL) or 12 mL of Lipofectamine Ò 2000 reagent. Then the plasmid and transfection reagent solutions were mixed (transfection mix), and the mixture was incubated for 20 min at ambient temperature. Each well of the culture plate was washed 3 times with 2 mL of PBS and exposed to 0.6 mL of preincubated transfection mix, and the culture plate was incubated for 4 h at 37 C. After incubation, each well received 3 mL of DMEM supplemented with 10% fetal bovine serum to terminate transfection, and the cell culture plate was incubated for 24 h at 37 C. Each well was washed 3 times with 2 mL of serum-free DMEM and received 2 mL of serum-free medium, and the cell culture plate was incubated for an additional 24 h at 37 C.
After incubation, the cell culture plate was placed on ice in a polyurethane box and left for 20 min. Each well of the plate was then washed 3 times with 2 mL of ice-cold PBS-BSA containing 1 mM CaCl 2 and 1 mM MgCl 2 (CM-PBS-BSA), and exposed to 1 mL of icecold CMF-PBS-BSA containing various concentrations of AFLoxLDL (or DiI-labeled oxLDL) in the presence and the absence of 0.64 mg/mL of nonlabeled oxLDL. The plate was placed on ice again in the polyurethane box, brought to a cold room, and incubated for 2.5 h with occasional agitation. After incubation the assay solutions were harvested, and the fluorescence values were determined as described above. The cells in each well were mechanically scraped with 1 mL of ice-cold PBS, transferred into a 1.5-mL microcentrifuge tube, and precipitated by centrifugation at 2;000 g for 3 min at 4
C. The resulting supernatants were discarded. After two rounds of washing with the addition of 1 mL of ice-cold PBS, centrifugation at 2;000 g for 3 min at 4 C, and removal of the supernatants, the cells in each microcentrifuge tube were exposed to 0.33 mL of 0.1 M NaOH and subjected to sonication for lysis. After centrifugation at 10;000 g for 10 min at 4 C, the resulting supernatants were collected. A 0.1-mL aliquot of the supernatants was transferred into a well of a 96-well assay plate (Asahi Techno Glass, Tokyo), followed by determination of the fluorescence value. The protein concentrations in the supernatants were determined using a BCA protein assay kit (Thermo Fisher Scientific Japan) with BSA as standard. The K d and B max values were determined as described above.
Determination of the K d and B max values for AFL-oxLDL binding to biotin-CD36 149{168 in a low-temperature environment. Wells pretreated with PBS-BSA containing 0.3 mM biotin-CD36 149{168 were washed 3 times with ice-cold CM-PBS-BSA and exposed to 0.1 mL of ice-cold CM-PBS-BSA containing various concentrations of AFL-oxLDL in the presence and the absence of 0.64 mg/mL of nonlabeled oxLDL. The plate was placed on ice in a polyurethane box, brought to a cold room, and incubated for 2.5 h with occasional agitation. The K d and B max values were determined as described above.
Results and Discussion
Evaluation of the binding of AFL-oxLDL to CD36 peptides immobilized on assay plates oxLDL labeled with Na 125 I, [13] [14] [15] a lipophilic and fluorescent dye DiI, 18) or with an Alexa Fluor dye 16) has been found to be recognized by CD36 expressed in mammalian cells. In the present study, we used oxLDL labeled with fluorescence dyes as a probe to perform assays under standard laboratory conditions. Preliminary experiments indicated that, by using the multiwell plate reader in our laboratory, fluorescence was detected more robustly, sensitively, and reliably from samples of CD36-expressing COS-1 cells incubated with AFLoxLDL than from those incubated with DiI-labeled oxLDL. For this reason, we adopted AFL-oxLDL as probe.
Of several synthetic peptides, each of which harbored the oxLDL-binding site on human CD36, one spanning amino acids 154 to 168 was found to be most effective at inhibiting the binding of 125 I-labeled oxLDL to CD36-expressing HEK293 cells and GST-CD36 118{182 immobilized onto glutathione-coated beads. 15) Based on these data, first we prepared a peptide corresponding to amino acids 154 to 168 of mouse CD36 conjugated with biotin at the N-terminus, designated biotin-CD36 154{168 (Fig. 1A) , and examined to determine whether the peptide immobilized on streptavidin-coated plates would interact with AFL-oxLDL. The fluorescence values did not differ considerably between the wells pretreated with biotin-CD36 154{168 at a concentration of 50 mM and then incubated with PBS-BSA containing AFL-oxLDL alone and the peptide-untreated control wells and incubated with PBS-BSA containing AFL-oxLDL alone (Fig. 1B) . In the wells pretreated with biotin-CD36 154{168 , the fluorescence values were not different irrespective of the presence or absence of nonlabeled oxLDL (Fig. 1B) . Comparable results were obtained using wells pretreated with biotin-CD36 154{168 at concentrations of 100 and 200 mM (data not shown). These results indicated that immobilized biotin-CD36 154{168 interacted poorly or not at all with AFL-oxLDL.
Next we prepared another N-terminally-biotinylated peptide, corresponding to amino-acid residues 149 to 168 of mouse CD36, designated biotin-CD36 149{168 (Fig. 1A) , and tested the binding interaction between the peptide immobilized on assay plates and AFL-oxLDL. The fluorescence values were considerably higher in the wells pretreated with biotin-CD36 149{168 and then incubated with PBS-BSA containing AFL-oxLDL alone than in the untreated control wells incubated with the same solution (Fig. 1B) . As for the wells pretreated with biotin-CD36 149{168 , the fluorescence values were significantly lower in those incubated in the presence of nonlabeled oxLDL than in those incubated in the absence of nonlabeled oxLDL (Fig. 1B) . These results indicate specific binding interaction between biotin-CD36 149{168 and AFL-oxLDL. On the other hand, AFLoxLDL exhibited poor or no binding in the assay plates pretreated with a variant of biotin-CD36 149{168 with a scrambled amino acid sequence, designated biotin-CD36 149{168 (scramble) (Fig. 1A, B) . This indicates that the amino-acid sequence of biotin-CD36 149{168 is critical in binding interaction with AFL-oxLDL.
The reason for the poor or absent binding between biotin-CD36 154{168 and AFL-oxLDL is unclear. One explanation is that AFL-oxLDL is barely accessible to the putative core of the binding site (corresponding to CD36 amino acids 160 to 168) 15) within the 15-aminoacid peptide under conditions in which it is immobilized on assay supports. In other words, the N-terminal 5-amino-acid stretch (Tyr-Gln-Asn-Ser-Phe) might allow the putative core to interact with AFL-oxLDL. Alternatively, poor or no ability of biotin-CD36 154{168 to interact with AFL-oxLDL may be due merely to the low solubility of the peptide. In any event, the use of biotin-CD36 154{168 is not suitable in evaluating and characterizing the binding between CD36 and oxLDL/oxPL. Lys164 and Lys166 on human CD36 have been found to be indispensable for binding interaction with oxLDL (Fig. 1A) . 15) To validate this, we prepared a variant of biotin-CD36 149{168 in which two lysine residues, corresponding to amino acids 164 and 166 of CD36, were changed to a glutamic acid residue, designated biotin-CD36 149{168 (K164E/K166E) (Fig. 1A) . We tested the binding interaction between the peptide immobilized on assay plates and AFL-oxLDL. We found no evidence that AFL-oxLDL bound to the plates pretreated with the peptide (Fig. 1B) . This indicates that the two lysine residues on biotin-CD36 149{168 are essential for binding interaction with AFL-oxLDL, and suggests that the importance of the residues is conserved across diverse animal species. Binding efficiencies to 125 I-labeled oxLDL are known to be similar between wild-type CD36 and a variant in which Lys164 and Lys166 are both changed to an arginine residue.
15) Positivelycharged side chains at positions 164 and 166 on CD36 appear to be essential for binding interaction with oxLDL/oxPL. The specific structural contexts of oxPL in interaction with these charged side chains of CD36 await further investigation.
Further characterization of the specific binding between biotin-CD36 149{168 and AFL-oxLDL
We further characterized the specific binding between biotin-CD36 149{168 and AFL-oxLDL. Nonlabeled oxLDL inhibits AFL-oxLDL-biotin-CD36 149{168 binding in a concentration-dependent manner, with maximal inhibition at a concentration of 0.64 mg/mL (Fig. 2A) .
The value for specific binding almost reached maximal level when the assay plate was pretreated with biotin-CD36 149{168 at a concentration of 50 mM (Fig. 2B) .
The specific binding of AFL-oxLDL to the plates pretreated with 50 mM biotin-CD36 149{168 exhibited a dose-dependent saturation pattern (Fig. 2C) . By fitting the progress curve of the amount of AFL-oxLDL bound to a well of the plate versus the concentration of free AFL-oxLDL in the well (Supplemental Fig. S1 ; see Biosci. Biotechnol. Biochem. Web site) to the theoretical curve using equation (1), the K d and B max values were determined to be 5.7 mg/mL and 7.1 ng/well respectively.
Evaluation of the abilities of oxidized and nonoxidized PL species to inhibit AFL-oxLDL-biotin-CD36 149{168 binding
The binding of 125 I-labeled oxLDL to CD36-expressing HEK293 cells was found to be inhibited efficiently by oxPL species such as KDdiA-PC and KOdiA-PC, but poorly or not at all by nonoxidized PL species such as PAPC. 13, 14) In the present study, we investigated to determine whether KDdiA-PC, KOdiA-PC, or PAPC inhibits AFL-oxLDL-biotin-CD36 149{168 binding. Wells pretreated with biotin-CD36 149{168 were incubated with AFL-oxLDL in the absence and the presence of various concentrations of PL species. KDdiA-PC and KOdiA-PC inhibited binding in a concentration-dependent manner, with half-maximal inhibition at about 0.25 and 0.31 mM respectively (Fig. 3) . On the other hand, PAPC exhibited no ability to inhibit binding at the concentrations tested (Fig. 3) . These results suggest that biotin-CD36 149{168 has ligand specificity similar to that of the oxLDL/oxPL-binding site on full-length CD36.
We assessed the inhibition pattern of KDdiA-PC for AFL-oxLDL-biotin-CD36 149{168 binding. If the K d value for binding is higher in the presence of KDdiA-PC than in its absence and the B max values are similar irrespective of its presence or absence, a competitive pattern of inhibition is indicated. 17) In the presence of 0.25 mM KDdiA-PC, specific binding also exhibited a saturation pattern. The curve of the amount of AFLoxLDL bound to a well of the plate versus the concentration of free AFL-oxLDL in the well (Supplemental Fig. S1 ; see Biosci. Biotechnol. Biochem. Web site) gave K d and B max values of 22 mg/mL and 6.0 ng/ well respectively. A comparison of these kinetic values with those obtained in assays in the absence of KDdiA-PC (e.g., from the data presented in Fig. 2C ) led to the conclusion that the oxPL species serves as a competitive inhibitor of AFL-oxLDL binding to biotin-CD36 149{168 . By equation (2), the K i value of KDdiA-PC for binding was determined to be 83 mM. The results obtained using KDdiA-PC suggest that immobilized biotin-CD36 149{168 interacts with AFL-oxLDL by recognition of the oxPL moieties.
Comparison of the binding affinity of AFL-oxLDL for biotin-CD36 149{168 with that for full-length CD36
We compared the binding affinity of AFL-oxLDL to biotin-CD36 149{168 with that to full-length CD36 expressed on the surfaces of living cells. We used COS-1 cells as the host line for protein overexpression. To assess binding to CD36 on the surfaces of the cells (or to avoid cellular uptake and degradation of AFL-oxLDL), assays were done in a low-temperature environment. The transfected cells were exposed to an ice-cold solution containing AFL-oxLDL, placed on ice, and incubated in a cold room. Calcium and magnesium ions were included in the assay solution to prevent cell detachment during incubation. Under these assay conditions, we detected specific, saturable binding of AFLoxLDL to the cells transiently transfected with pcDNAmCD36. The K d and B max values were determined to be 1.1 mg/mL and 0.18 mg/mg of cell protein respectively (Supplemental Fig. S2, upper panel) . On the other hand, no apparent specific binding was found between AFLoxLDL and the cells transfected with parental pcDNA3.1(þ) vector (data not shown), indicating that the binding of AFL-oxLDL to the COS-1 cells transfected with pcDNA-mCD36 was exclusively to be attributed to the binding to the protein molecules exogenously expressed on the surfaces of the cells.
Assays using biotin-CD36 149{168 were also done in a low-temperature environment. Unlike the assays at ambient temperature, the values for specific binding were highest when using assay plates pretreated with biotin-CD36 149{168 at a concentration of 0.3 mM. Under these conditions, the specific binding also exhibited a dose-dependent saturation pattern, with K d and B max values of 8.5 mg/mL and 9.6 ng/well respectively (Supplemental Fig. S2, lower panel) . The K d value A, Inhibition by nonlabeled oxLDL of AFL-oxLDL binding to immobilized biotin-CD36 149{168 . Wells of streptavidin-coated plates pretreated with 50 mM biotin-CD36 149{168 were incubated with PBS-BSA containing 8 mg/mL of AFL-oxLDL in the presence and the absence of nonlabeled oxLDL at the concentrations indicated. Each fluorescence value for the individual peptide-treated wells was obtained by subtracting the mean fluorescence value for the peptideuntreated wells incubated with AFL-oxLDL alone. The mean fluorescence value for the wells pretreated with biotin-CD36 149{168 and then incubated with AFL-oxLDL alone was taken to be 1.0. Data are expressed as mean AE SD for three independent wells. B, Investigation of the concentration of biotin-CD36 149{168 sufficient to achieve maximaum values for the specific binding of AFL-oxLDL. Wells of streptavidin-coated plates were pretreated with biotin-CD36 149{168 at the concentrations indicated. The plate was then incubated with PBS-BSA containing 8 mg/mL of AFL-oxLDL in the presence and the absence of 0.64 mg/mL of nonlabeled oxLDL. The mean value for the specific binding from the wells pretreated with biotin-CD36 149{168 at a concentration of 50 mM was taken to be 1.0. Data are expressed as mean AE SD for three independent wells. C, Dose-dependent saturable binding of AFL-oxLDL to immobilized biotin-CD36 149{168 . Wells pretreated with 50 mM biotin-CD36 149{168 were incubated with PBS-BSA containing AFL-oxLDL at the concentrations indicated in the absence and the presence of 0.64 mg/ mL of nonlabeled oxLDL. Each of the fluorescence values for total and nonspecific binding was obtained by subtracting the mean background value for the wells incubated with PBS-BSA alone (with PBS-BSA containing no AFL-oxLDL). The mean fluorescence value for wells incubated with 10 mg/mL of AFL-oxLDL in the absence of nonlabeled oxLDL was taken to be 1.0. Values for specific binding were obtained by subtracting the values for total binding from those for nonspecific binding at each concentration of AFL-oxLDL. Data are expressed as mean AE SD for three independent wells. Wells pretreated with 50 mM biotin-CD36 149{168 were incubated with PBS-BSA containing 8 mg/mL of AFL-oxLDL in the presence and the absence of PL species at the concentrations indicated. Each fluorescence value from individual peptide-treated wells was obtained by subtracting the mean fluorescence value for the peptide-untreated wells incubated with AFL-oxLDL alone. The mean fluorescence value for wells pretreated with biotin-CD36 149{168 and then treated with AFL-oxLDL alone was taken to be 1.0. The data for KDdiA-PC, KOdiA-PC, and PAPC are indicated by white, grey, and black circles respectively. Data are expressed as mean AE SD for three independent wells. was about 8 times higher for binding between AFLoxLDL and biotin-CD36 149{168 than for that between AFL-oxLDL and the full-length CD36 expressed by the COS-1 cells. One possible explanation of the difference is that AFL-oxLDL gained access to the core of binding site on full-length CD36 more easily than to that on biotin-CD36 149{168 immobilized on assay plates. Alternatively, the difference in the K d values might be attributable to that in the binding strength and/or stability to supports. In fact, biotin-CD36 149{168 molecules bind to assay plates only through a biotinstreptavidin interaction, whereas CD36 molecules expressed by COS-1 cells anchor tightly to the plasma membranes.
In the present study, we found that AFL-oxLDL bound specifically and saturably to biotin-CD36 149{168 immobilized on assay plates, and that binding was inhibited by KDdiA-PC and KOdiA-PC, but not by PAPC. This led us to conclude that this assay system, using biotin-CD36 149{168 , provides a fast, reliable, and reproducible method of detecting the binding between CD36 and oxLDL/oxPL. Furthermore, the system allows simple and low-cost high-throughput screening for competitors of oxLDL/oxPL binding to CD36. Such competitors can be expected to prove useful as antiaging, diabetes, or atherosclerosis drugs.
